Serum lipoproteins in the epidemiology of ischaemic heart disease
Reinis, Z.; Heyrovský, A.; Marcan, K.; Horáková, D.; Klimesová, A.; Reisenauer, R.
Casopis Lekaru Ceskych 114(34-35): 1067-1069
1975
ISSN/ISBN: 0008-7335 PMID: 1175197 Document Number: 89466
Document emailed within 1 workday
Related Documents
Reinis, Z.; Pokorný, J.; Bazika, V.; Tiserová, J.; Gorican, K.; Horáková, D.; Stuchlíková, K.; Havránek, T.; Hrabovský, F. 1983: Epidemiology and prevention of ischaemic heart disease in automobile industry workers Czechoslovak Medicine 6(1): 53-54Vasantha, V.C.; Somayajulu, G.L.; Pai, H.S. 1985: Serum alpha 1-antitrypsin activity in ischaemic heart disease Journal of the Indian Medical Association 83(9): 297-299
Chakraborti, S.; Banerjee, P.K. 1974: Serum cholesterol in relation to blood groups in ischaemic heart disease Journal of the Indian Medical Association 63(5): 150-152
Raman, B.N.; Vij, S.C.; Maitrya, B.B. 1976: Blood cholesterol and serum magnesium in health and ischaemic heart disease Journal of the Indian Medical Association 66(6): 124-126
Awan, Z.A.; Baseer, A. 1995: A study on serum triglyceride and lipoproteins cholesterol in coronary heart disease patients Jpma. Journal of the Pakistan Medical Association 45(10): 263-266
Haviar, V.; Riecanský, L.; Kusá, O.; Luknárová, O. 1972: Effects of heparin and clofibrate on blood-serum lipid levels in patients with ischaemic heart disease Cor et Vasa 14(3): 188-196
Bosch, V.; Santana, C.; Pieters, G. 1970: Serum lipids and lipoproteins in normal persons and in patients with ischemic heart disease in Venezuela Acta Cientifica Venezolana 21(3): 94-97
Lewis, B.; Chait, A.; Wootton, I.D.; Oakley, C.M.; Krikler, D.M.; Sigurdsson, G.; February, A.; Maurer, B.; Birkhead, J. 1974: Frequency of risk factors for ischaemic heart-disease in a healthy British population. With particular reference to serum-lipoprotein levels Lancet 1(7849): 141-146
1980: W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators Lancet 2(8191): 379-385
Yarnell, J.W.; Limb, E.S.; Layzell, J.M.; Baker, I.A. 1992: Height: a risk marker for ischaemic heart disease: prospective results from the Caerphilly and Speedwell Heart Disease Studies European Heart Journal 13(12): 1602-1605
Golan, D.T.; Kursbaum, A. 1976: Anti-heart autoantibodies in ischaemic heart disease patients Clinical and Experimental Immunology 26(1): 86-90
1997: Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group Lancet 349(9049): 375-380
Nony, P.; Boissel, J.P.; Girard, P.; Leizorovicz, A.; Lievre, M.; Chifflet, R. 1992: Relative efficacy of angiotensin converting enzyme inhibitors on mortality of patients with congestive heart failure: implications of randomized trials and role of the aetiology (ischaemic or non-ischaemic) of heart failure European Heart Journal 13(8): 1101-1108
Bashir, R.; Khan, A.; Yousaf, M. 1996: Angiographically documented coronary artery disease in asymptomatic middle aged men suspected of silent ischaemic heart disease Jpma. Journal of the Pakistan Medical Association 46(10): 225-228
Law, M.R.; Wald, N.J. 1999: Homocysteine and ischaemic heart disease Haematologica 84 Suppl Eha-4: 57-60
Wojtczak, A.; Skretkowicz, J. 2007: Genetics in ischaemic heart disease Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 23(133): 5-8
Christie, J. 2011: Ischaemic heart disease prevention NursingTimes 107(30-31): 20
Van Assche, F.A.; Aerts, L.; Holemans, K. 1994: Low birthweight and ischaemic heart disease Lancet 343(8899): 731-732
Lhotka, J.; Stuchlíková, E.; Klimesová, A. 1971: Changes in the pericardium in ischaemic heart disease Acta Universitatis Carolinae. Medica 17(7): 573-580
Violi, F.; Iuliano, L.; Iullano, L. 1997: Antioxidants and ischaemic heart disease Lancet 350(9078): 667-668